The article discusses the growing evidence supporting the use of colchicine in treating atherosclerotic cardiovascular disease (ASCVD). Key points:
Colchicine's mechanism of action: It dampens inflammatory markers on neutrophils, reducing their ability to adhere to inflamed or injured endothelium, which is a key contributor to plaque formation and rupture.
Clinical evidence:
Preliminary data from a neutrophil biomarker substudy of CLEAR SYNERGY showed that colchicine reduced neutrophil adhesion to endothelial cells, neutrophil chemotaxis, and neutrophil activation, potentially inhibiting inflammasomes and decreasing IL-1β production.
Colchicine has been consistently shown to reduce the risk of recurrent myocardial infarction in patients with cardiovascular disease or at high risk, based on both retrospective and prospective studies.
Barriers to wider adoption: Confusion around the approved 0.5 mg dose for cardiovascular disease versus the 0.6 mg dose for gout, potential gastrointestinal side effects, and polypharmacy in these patients.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Richard Mark... at www.medscape.com 05-06-2024
https://www.medscape.com/viewarticle/evidence-builds-support-colchicine-treating-atherosclerotic-2024a10008onDeeper Inquiries